CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Company) appointed Mr. Michael Metzger as a director of the Board
as of January 20, 2017, to serve until the Companys next annual
meeting of shareholders and until his successor is duly elected
and qualified. The Board also appointed Mr. Metzger to serve as a
member of the Audit Committee. The Board determined that Mr.
Metzger is independent and financially literate to the applicable
rules and regulations of the Securities and Exchange Commission
(the SEC) and NASDAQ.
accordance with the Companys Director Compensation Policy as in
effect from time to time. In connection with his appointment to
the Board and in accordance with the Companys Director
Compensation Policy as currently in effect, Mr. Metzger received
a grant under the Companys 2015 Equity Incentive Plan (the Plan)
of 20,121 restricted stock units. The restricted stock units will
vest on the first to occur of (1) January 20, 2018, (2)
immediately prior to the first annual meeting of the Companys
shareholders that occurs in 2018 and at which one or more members
of the Board are to be elected, or (3) immediately prior to the
occurrence of a Change in Control (as such term is defined in the
Plan), subject to Mr. Metzgers continued service through such
date or event.
standard indemnification agreement with the Company substantially
in the form previously approved by the Board, which is filed as
Exhibit 10.1 to the Companys Current Report on Form 8-K filed
with the SEC on June 2, 2014, and is incorporated by reference
herein.
the appointment of Mr. Metzger as a director to the Companys
Board as set forth in Item 5.02 of this Current Report on Form
8-K. A copy of such press release is furnished as Exhibit 99.1 to
this report. This information shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, and is not incorporated by reference into any filing of
the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.
|
Exhibit
No.
|
Description
|
Location
|
||
|
99.1
|
Press Release issued by CTI BioPharma Corp. on January
24, 2017. |
Furnished herewith.
|
About CTI BIOPHARMA CORP. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer. CTI BIOPHARMA CORP. (NASDAQ:CTIC) Recent Trading Information
CTI BIOPHARMA CORP. (NASDAQ:CTIC) closed its last trading session down -0.09 at 5.10 with 424,872 shares trading hands.